Business Context and Reporting Period
This Form 8-K filing by AnaptysBio, Inc. (ANAB) reports a corporate governance event dated November 26, 2021. The company is a Delaware corporation with its principal executive offices in San Diego, California, and its common stock trades on the Nasdaq Global Market.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the appointment of a new director and associated compensatory arrangements.
Material Changes
The primary material change reported is the appointment of Mr. Daniel Faga as a Class I director on the Board of Directors, effective immediately on November 26, 2021. In connection with this appointment, the following compensatory arrangements were established:
- Pro Rata Retainer Option: A stock option to purchase 2,321 shares of common stock at the closing sale price on November 26, 2021, vesting in full on February 10, 2022.
- Annual Retainer Option: A stock option to purchase 11,000 shares of common stock at the closing sale price on November 26, 2021, vesting monthly over three years, subject to continued service.
Mr. Faga also entered into the Company's standard form of indemnification agreement.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding business outlook, financial guidance, or specific risks. It confirms there are no undisclosed arrangements or understandings regarding Mr. Faga's selection and no family relationships with other directors or officers that would require disclosure under Regulation S-K.
Investor Verification Checklist
- Verify the vesting schedule and exercise price of the 13,321 total shares of stock options granted to Mr. Faga.
- Confirm the impact of this new director appointment on the composition of the Board of Directors.
- Review the standard indemnification agreement (previously filed as Exhibit 10.1 to Form S-1) for any specific liabilities or protections.